Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance

Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: Aberrant activation of the HH-Gli signaling pathway in acquired resistance

Medullary thyroid carcinoma (MTC) is a malignant tumor with challenging management. Multi-targeted kinase inhibitors (MKI) and tyrosine-kinase inhibitors (TKI) with high specificity for RET protein are approved for advanced MTC treatment. However, their efficacy is hindered by evasion mechanisms of...

Full description

Bibliographic Details
Main Authors: Sofia Trocchianesi, Agnese Po, Anna Citarella, Zaira Spinello, Aurelia Rughetti, Zein Mersini Besharat, Tanja Milena Autilio, Valeria Pecce, Antonella Verrienti, Rossella Elisei, Cosimo Durante, Giuseppina Catanzaro, Elisabetta Ferretti
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Medullary thyroid carcinoma
Pralsetinib
HH-Gli signaling
Resistance to therapy
Normoxia
Hypoxia
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332223007850

Internet

http://www.sciencedirect.com/science/article/pii/S0753332223007850

Similar Items